Interpretation of cytogenetic and molecular results in patients treated for CML.
about
Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.How we will treat chronic myeloid leukemia in 2016.Benefits, issues, and recommendations for personalized medicine in oncology in CanadaST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model.Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia.Molecular monitoring 101: helping your patients with chronic myeloid leukemia to understand the meaning of molecular response.
P2860
Interpretation of cytogenetic and molecular results in patients treated for CML.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Interpretation of cytogenetic and molecular results in patients treated for CML.
@ast
Interpretation of cytogenetic and molecular results in patients treated for CML.
@en
Interpretation of cytogenetic and molecular results in patients treated for CML.
@nl
type
label
Interpretation of cytogenetic and molecular results in patients treated for CML.
@ast
Interpretation of cytogenetic and molecular results in patients treated for CML.
@en
Interpretation of cytogenetic and molecular results in patients treated for CML.
@nl
prefLabel
Interpretation of cytogenetic and molecular results in patients treated for CML.
@ast
Interpretation of cytogenetic and molecular results in patients treated for CML.
@en
Interpretation of cytogenetic and molecular results in patients treated for CML.
@nl
P2093
P2860
P1433
P1476
Interpretation of cytogenetic and molecular results in patients treated for CML.
@en
P2093
Carlos E Vigil
Elizabeth A Griffiths
Eunice S Wang
Meir Wetzler
P2860
P304
P356
10.1016/J.BLRE.2011.02.001
P577
2011-03-17T00:00:00Z